Acute Myocardial Infarction
Conditions
Interventions
Experimental Group:After returning to the ward after emergency PCI, the injection of Xuesaitong was administered at a dose of 0.2g. It was diluted with 250ml of 0.9% sodium chloride injection and admi
Control Group:Basic Western medicine treatment includes: 100mg of enteric-coated aspirin tablets, taken orally once a day
90mg of ticagrelor, taken orally twice a day
20mg of atorvastatin calcium tablets, taken orally once every night
and routine medication for the underlying diseases.
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
42 Years to 82 Years
Inclusion criteria
Inclusion criteria: (1) It must meet both the Western medical diagnostic criteria for acute myocardial infarction and the diagnostic criteria of traditional Chinese medicine for "chest pain syndrome". (2) No gender restrictions. Age range: 42 years and above, 82 years and below. Voluntary as a test subject and abide by the trial rules and requirements. (3) Patients who returned to the ward after successful emergency PCI surgery; successful surgery criteria: The culprit vessel has been completely revascularized, residual stenosis is less than 20%, TIMI grade III blood flow, and no serious complications such as death or recurrence of acute myocardial infarction occurred during hospitalization.
Exclusion criteria
Exclusion criteria: (1) Those with a large myocardial infarction area and who have developed cardiogenic shock, with a higher risk of recent death. (2) Those who cannot tolerate statin drugs, or have severe liver and kidney dysfunction. (3) Those who have a history of old myocardial infarction in the past, or those with malignant tumors, severe infectious diseases, inflammatory diseases, hematological diseases, acute cerebral infarction, etc. (4) Other individuals whose participation in this study is deemed inappropriate by the researchers. (5) Those who have participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory cytokines (IL-1ß, IL-6, TNF-a); | — |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial injury biomarkers (CK, CK-MB, cTnT, NT-proBNP);Electrocardiogram;Cardiac ultrasound examination; | — |
Countries
China
Contacts
Public ContactFeng Can
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed